News & Events CTI CEO to Moderate Session at 8th Annual Advanced Therapies Summit

CTI CEO to Moderate Session at 8th Annual Advanced Therapies Summit

March 13, 2018

CTI CEO to Moderate Session at 8th Annual Advanced Therapies Summit

FOR IMMEDIATE RELEASE [Covington, KY ~ March 13, 2018] 

CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization will moderate a session of the Alliance for Regenerative Medicine (ARM) 8th Annual Advanced Therapies Summit on Wednesday, March 14, 2018 in Amsterdam. Timothy J. Schroeder, Founder and Chief Executive Officer, will moderate the plenary session, "Clinical and Commercial Momentum: How can the European advanced therapy medicinal product (ATMP) sector take advantage of recent successes to support further investment and growth?" 

"We're honored to be a part of the Advanced Therapies Summit, both as a moderator and sponsor of the meeting," remarks Schroeder. "CTI is an expert in regenerative medicine, with more than 40% of our current studies in cell and gene therapy across more than 25 countries, and contributions to the world's first approved cell therapy product. We believe that this expertise and our partnership with the Alliance demonstrates our belief that diagnosis and treatment paradigms will change dramatically in the near future based on these advances."

ARM is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide.

Timothy Schroeder, CEO and Founder of CTI, has more than 35 years of clinical, academic and industry experience in global drug and device development programs. CTI, founded in 1999, is a multi-national research firm with associates in North America, Europe, Latin America and Asia-Pacific. The firm has supported more than 110 drug and device approvals, and currently works on behalf of approximately 140 global pharmaceutical and biotechnology companies. Prior to founding CTI, Tim held numerous faculty positions with the University of Cincinnati College of Medicine. He was also the founding Executive Vice President of Clinical Development at SangStat Medical Corporation, which went public in 1995. Tim is currently a board member for more than a dozen corporate and non-profit organizations, including Xavier University, which he attended. Tim was named as an EY Entrepreneur of the Year in 2015 and was recognized as Top Leader by the Enquirer Media in 2016.


About CTI Clinical Trial and Consulting Services

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit

CTI CEO to Moderate Session at 8th Annual Advanced Therapies Summit

Subscribe to our mailing list

* indicates required